A further confounding variable for the assignment of anti-estrogen therapy is the fact that ER antagonists (both SERMS and SERDs) function as GPER agonists, which aligns with the finding that GPER is associated with tamoxifen resistance in breast cancer patients (103). The gene discussed is ESR1; the disease is breast cancer.